Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Truist Securities analyst Richard Newitter maintains Edwards Lifesciences (NYSE:EW) with a Hold and lowers the price target ...
Oppenheimer analyst Suraj Kalia maintains Edwards Lifesciences (NYSE:EW) with a Outperform and maintains $90 price target.
UBS analyst Danielle Antalffy maintains Edwards Lifesciences (NYSE:EW) with a Neutral and lowers the price target from $90 t...
Barclays analyst Matt Miksic maintains Edwards Lifesciences (NYSE:EW) with a Overweight and lowers the price target from $90...
Wells Fargo analyst Larry Biegelsen maintains Edwards Lifesciences (NYSE:EW) with a Overweight and lowers the price target f...
- SEC Filing
Edwards Lifesciences (NYSE:EW) today announced the results from the RHEIA Trial, a first-of-its-kind trial focused exclusively ...
